Replimune is saying goodbye to a further 161 employees across two Massachusetts sites as the company continues to reel from ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...

But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...

Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset ...

President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear ...

In another sign that the biotech IPO market is heating back up, Odyssey Therapeutics has made a fresh announcement of its ...

Roche is handing over $595 million to bolster its Foundation Medicine business with a deal to snap up SAGA Diagnostics. | ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...

A phase 2 trial combining Agenus’ and MiNK Therapeutics’ cancer candidates has missed its primary endpoint. But with the ...

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...

| Bioprocessing is evolving rapidly in a shifting landscape of innovative and complex products, processes and technologies.